GlassScriptPhysician profile
Robert J Karl
NPI 1073595435
$5,917.34
in general payments reported to CMS, 2019-2025
49 companies · $751 in 2025
The $751 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $641 · 2021: $1,569 · 2022: $1,075 · 2023: $182 · 2024: $918 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $776.04 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $705.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $452.46 | 2019-2025 | |
| Amgen INC. | $415.11 | 2019-2025 | Evenity, Otezla, Repatha |
| Amarin Pharma, INC. | $323.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $218.34 | 2019-2024 | Shingrix |
| Janssen Pharmaceuticals, INC | $205.32 | 2021-2025 | Spravato |
| Daiichi Sankyo INC. | $201.58 | 2019-2025 | Injectafer |
| Pfizer INC. | $190.98 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.02 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $171.04 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.52 | 2021-2025 | |
| Astellas Pharma US INC | $153.89 | 2019-2023 | Veozah |
| Esperion Therapeutics, INC. | $144.72 | 2021-2022 | |
| Lilly USA, LLC | $140.77 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $131.16 | 2019-2022 | |
| Corcept Therapeutics | $102.67 | 2024-2025 | Korlym |
| Abbott Laboratories | $97.69 | 2021-2025 | Freestyle Libre 3 |
| Abiomed | $97.24 | 2024-2025 | Impella |
| Sumitomo Pharma America, INC. | $96.85 | 2023-2024 | Gemtesa |
| Novo Nordisk INC | $82.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $81.86 | 2021-2024 | Verquvo |
| Medtronic, INC. | $76.20 | 2021-2024 | Corevalve Evolut R |
| Phathom Pharmaceuticals, INC. | $67.17 | 2025 | Voquezna |
| Dexcom, INC. | $65.23 | 2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Antares Pharma, INC. | $54.41 | 2019-2025 | Xyosted |
| Allergan, INC. | $39.09 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.82 | 2024-2025 | Caplyta |
| Alexion Pharmaceuticals, INC. | $33.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $32.61 | 2022 | |
| Genentech USA, INC. | $30.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.49 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $27.83 | 2021-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $26.96 | 2019-2020 | |
| Inari Medical, INC. | $26.82 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Recor Medical INC | $24.47 | 2024 | Paradise Renal Denervation System |
| Mannkind Corporation | $24.14 | 2019 | |
| Seqirus USA INC | $23.62 | 2020-2022 | |
| Philips North America LLC | $19.80 | 2020 | |
| Eisai INC. | $19.14 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $17.49 | 2021 | |
| Axsome Therapeutics, INC. | $15.67 | 2025 | Symbravo |
| Adlon Therapeutics L.P. | $15.52 | 2020 | |
| Agios Pharmaceuticals, INC. | $15.10 | 2023 | Pyrukynd |
| Idorsia Pharmaceuticals US INC | $14.60 | 2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $14.15 | 2020 | |
| Almatica Pharma LLC | $11.97 | 2021 | |
| Acadia Pharmaceuticals INC | $11.60 | 2021 | |
| Sanofi Pasteur INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Karl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.